Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of bedaquiline compared to standard treatments to prevent tuberculosis disease in people living with HIV and close contacts of adults with drug-susceptible or rifampin-resistant tuberculosis. This Phase IIIII open-label trial aims to show that 4 weeks of bedaquiline is not less effective than current WHO-recommended regimens for preventing tuberculosis in these high-risk groups. Participants are assigned to one of three treatment groups 4 weeks of daily bedaquiline, 3 months of weekly isoniazid and rifapentine, or 6 months of daily levofloxacin. The study includes groups at high risk, such as children, adolescents, adults, pregnant people, and people living with HIV, with treatments adjusted by weight or age. Treatment durations vary by regimen, and those with rifampin-resistant tuberculosis receive levofloxacin. During the study, participants undergo safety and treatment completion assessments up to 18 or 36 weeks depending on the group. Researchers monitor for adverse events, treatment adherence, and incidence of tuberculosis disease for up to 72 weeks after treatment starts. Laboratory tests, chest x-rays, and pregnancy tests are conducted before enrollment, and safety is closely followed throughout the study period lasting over one year from treatment initiation.
Actively Recruiting
Researchers are conducting an international, open-label, randomized clinical trial called PRISM-TB to study treatment options for people with fluoroquinolone-susceptible multidrug-resistant or rifampin-resistant pulmonary tuberculosis FQ-S MDRRR-TB. This Phase 23 trial has two stages and aims to identify the preferred BPaLM treatment strategy with shorter or longer durations and to evaluate if this strategy is as effective as the current standard treatment at Week 73. The study uses a multi-arm, multi-stage design with a pragmatic, stratified medicine approach. Participants will be randomly assigned to one of several treatment arms. In Stage 1, they receive either the control standard of care regimen typically lasting 24 weeks with bedaquiline, pretomanid, linezolid, and moxifloxacin 6BPaLM, or one of two investigational strategies including 17 weeks of these drugs 4BPaLM or a stratified approach with 13 weeks for easier-to-treat cases and 24 weeks for harder-to-treat cases. In Stage 2, participants receive either the control regimen or the preferred treatment strategy identified from Stage 1. Drug doses and durations may be adjusted based on current international guidelines and local standards. Participants are involved for up to 73 weeks, during which their health and treatment effects are closely monitored. Researchers evaluate the primary outcome using the Desirability of Outcome Ranking DOOR at Week 73. Additional assessments include mortality and adverse events up to 28 weeks. Participants provide informed consent and must be available for home visits and phone calls. Safety is monitored throughout, and follow-up visits ensure collection of clinical data to assess treatment efficacy and tolerability over time.